| Old Articles: <Older 7631-7640 Newer> |
|---|
 |
The Motley Fool
July 12, 2011
Luke Timmerman |
Seattle Genetics' New "Empowered Antibody" Looks Clean in FDA Staff Documents FDA reviews Seattle Genetics' Hodgkin's lymphoma drug.   |
The Motley Fool
July 12, 2011
Brian Orelli |
That's One Expensive BiTE Amgen licenses Micromet's BiTE antibody technology. |
The Motley Fool
July 12, 2011
Arundhati Parmar |
FDA Allows Expansion of St. Jude Study to Treat Severe Depression St. Jude moves forward with treatment for depression. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
Pharmaceutical Executive
July 1, 2011 |
Precious Mettle Taking Onyx Pharmaceuticals to new heights: CEO Tony Coles talks about the midsize company's transition from adolescence to adulthood. |
Pharmaceutical Executive
July 1, 2011
Mangesh Sai |
What the 2011 Census of India Reveals for Pharma What India's latest census tells us about current and future pharma opportunities. |
Pharmaceutical Executive
July 1, 2011
William Looney |
Planning Beyond the Petri Dish Pfizer's crizotinib development program combined organization, art, and science, and a large dose of unforeseen risk. |
Pharmaceutical Executive
July 1, 2011
William Looney |
Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them. |
Pharmaceutical Executive
July 1, 2011
Jill Wechsler |
Battles over Biosimilars Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game. |
Pharmaceutical Executive
July 1, 2011
Todd C. Davis |
Seeing the Fire Behind the Smoke While crafting license agreements involves all of the tactical tradeoffs expected in a negotiating dynamic, one should try to pay attention to these 10 licensing pitfalls. |
| <Older 7631-7640 Newer> Return to current articles. |
